Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

779 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction.
Roe MT, Green CL, Giugliano RP, Gibson CM, Baran K, Greenberg M, Palmeri ST, Crater S, Trollinger K, Hannan K, Harrington RA, Krucoff MW; INTEGRITI Investigators. Roe MT, et al. Among authors: gibson cm. J Am Coll Cardiol. 2004 Feb 18;43(4):549-56. doi: 10.1016/j.jacc.2003.09.039. J Am Coll Cardiol. 2004. PMID: 14975462 Free article. Clinical Trial.
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E; INTEGRITI Study Group. Gibson CM, et al. Circulation. 2004 Aug 10;110(6):679-84. doi: 10.1161/01.CIR.0000137912.11655.F6. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262838 Clinical Trial.
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E; EARLY ACS Steering Committee. Giugliano RP, et al. Among authors: gibson cm. Am Heart J. 2005 Jun;149(6):994-1002. doi: 10.1016/j.ahj.2005.03.029. Am Heart J. 2005. PMID: 15976780
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Among authors: gibson cm. Am Heart J. 2005 Oct;150(4):643-9. doi: 10.1016/j.ahj.2005.05.021. Am Heart J. 2005. PMID: 16209958
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.
Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, Roe MT. Patel MR, et al. Among authors: gibson cm. Am Heart J. 2006 Oct;152(4):641-7. doi: 10.1016/j.ahj.2006.02.035. Am Heart J. 2006. PMID: 16996828
779 results